The oral PCSK9 inhibitor enlicitide can change cholesterol management with high efficacy and improved adherence, said Ann Marie Navar, MD, PhD.
Ann Marie Navar, MD, PhD
Advertisement
Ann Marie Navar, MD, PhD, is an associate professor in the departments of internal medicine and population and data sciences at UT Southwestern Medical Center.
Articles by Ann Marie Navar, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance
3
Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups
4
Zanubrutinib Tops Rivals in Real-World CLL Survival Study
5